505341565 02/22/2019

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5388347

| SUBMISSION TYPE: | | NEW ASSIGNMENT | NEW ASSIGNMENT | | | | |
|--|--|---|-----------------|--|--|--|--|
| NATURE OF CONVEYANCE: | | ASSIGNMENT | | | | | |
| CONVEYING PARTY | ΔΑΤΑ | | | | | | |
| | | Name | Execution Date | | | | |
| HYDRA BIOSCIENCES | S, INC. | | 12/14/2018 | | | | |
| RECEIVING PARTY D | ΑΤΑ | | | | | | |
| Name: | Eli Lilly a | Eli Lilly and Company | | | | | |
| Street Address: | Lilly Corp | Lilly Corporate Center | | | | | |
| Internal Address: | Patent Di | Patent Division | | | | | |
| City: | Indianapo | Indianapolis | | | | | |
| State/Country: | INDIANA | INDIANA | | | | | |
| Postal Code: | 46285 | | | | | | |
| | | | | | | | |
| PROPERTY NUMBER | | Normale an | - | | | | |
| Property Type | | Number | _ | | | | |
| Application Number: | 12 | 2688241 | | | | | |
| CORRESPONDENCE | DATA | | | | | | |
| Fax Number:(317) | | 276-3861 | | | | | |
| | | , | | | | | |
| | | he e-mail address first; if that is un | | | | | |
| using a fax number, in | f provided; | he e-mail address first; if that is un if that is unsuccessful, it will be sei | | | | | |
| <i>using a fax number, i</i> Email: | f provided; pa | he e-mail address first; if that is un | | | | | |
| using a fax number, in | f provided; pa : El | he e-mail address first; if that is un if that is unsuccessful, it will be sen atents@lilly.com | | | | | |
| <i>using a fax number, in</i> Email: Correspondent Name | f provided; pa : El P. | he e-mail address first; if that is un if that is unsuccessful, it will be sei atents@lilly.com _I LILLY AND COMPANY | | | | | |
| <i>using a fax number, in</i> Email: Correspondent Name Address Line 1: | f provided; pa : El P. P. | he e-mail address first; if that is un if that is unsuccessful, it will be sei atents@lilly.com _I LILLY AND COMPANY O. BOX 6288 | nt via US Mail. | | | | |
| using a fax number, in Email: Correspondent Name Address Line 1: Address Line 2: | f provided; pa : El P. P. N | he e-mail address first; if that is un if that is unsuccessful, it will be set atents@lilly.com _I LILLY AND COMPANY O. BOX 6288 ATENT DIVISION | nt via US Mail. | | | | |
| using a fax number, in Email: Correspondent Name Address Line 1: Address Line 2: Address Line 4: | f provided; pa : El P P IN IVMBER: | he e-mail address first; if that is un if that is unsuccessful, it will be sel atents@lilly.com _I LILLY AND COMPANY O. BOX 6288 ATENT DIVISION IDIANAPOLIS, INDIANA 46206-6288 | nt via US Mail. | | | | |
| using a fax number, in Email: Correspondent Name Address Line 1: Address Line 2: Address Line 4: ATTORNEY DOCKET N NAME OF SUBMITTER | f provided; pa : El P P IN IVMBER: | he e-mail address first; if that is un if that is unsuccessful, it will be sel atents@lilly.com _I LILLY AND COMPANY O. BOX 6288 ATENT DIVISION IDIANAPOLIS, INDIANA 46206-6288 X22289A | nt via US Mail. | | | | |
| using a fax number, in Email: Correspondent Name Address Line 1: Address Line 2: Address Line 4: | f provided; pa : El P P IN IVMBER: | he e-mail address first; if that is un if that is unsuccessful, it will be set atents@lilly.com _I LILLY AND COMPANY O. BOX 6288 ATENT DIVISION IDIANAPOLIS, INDIANA 46206-6288 X22289A PATRICIA A FOOR | nt via US Mail. | | | | |
| using a fax number, in Email: Correspondent Name Address Line 1: Address Line 2: Address Line 4: ATTORNEY DOCKET N NAME OF SUBMITTER SIGNATURE: | f provided; pa : El P P IN IVMBER: | he e-mail address first; if that is un if that is unsuccessful, it will be sel atents@lilly.com _I LILLY AND COMPANY O. BOX 6288 ATENT DIVISION IDIANAPOLIS, INDIANA 46206-6288 X22289A PATRICIA A FOOR /Patricia A Foor/ | nt via US Mail. | | | | |
| using a fax number, in Email: Correspondent Name Address Line 1: Address Line 2: Address Line 4: ATTORNEY DOCKET N NAME OF SUBMITTER SIGNATURE: DATE SIGNED: | f provided; pa : El P P IVMBER: : | he e-mail address first; if that is un if that is unsuccessful, it will be set atents@lilly.com LI LILLY AND COMPANY O. BOX 6288 ATENT DIVISION IDIANAPOLIS, INDIANA 46206-6288 X22289A X22289A PATRICIA A FOOR /Patricia A Foor/ 02/22/2019 | nt via US Mail. | | | | |
| using a fax number, in Email: Correspondent Name Address Line 1: Address Line 2: Address Line 4: ATTORNEY DOCKET N NAME OF SUBMITTER SIGNATURE: DATE SIGNED: Total Attachments: 5 | f provided; pa : El P. P/ IN IUMBER: : | he e-mail address first; if that is un if that is unsuccessful, it will be sel atents@lilly.com LI LILLY AND COMPANY O. BOX 6288 ATENT DIVISION IDIANAPOLIS, INDIANA 46206-6288 X22289A PATRICIA A FOOR /Patricia A Foor/ 02/22/2019 | nt via US Mail. | | | | |
| using a fax number, in Email: Correspondent Name Address Line 1: Address Line 2: Address Line 2: Address Line 4: ATTORNEY DOCKET N NAME OF SUBMITTER SIGNATURE: DATE SIGNED: Total Attachments: 5 source=Patent Assignme source=Patent Assignme | f provided; pa : El P. P/ IVMBER: : : : : : : : : : : : : : : : : : : | he e-mail address first; if that is un if that is unsuccessful, it will be sel atents@lilly.com LI LILLY AND COMPANY O. BOX 6288 ATENT DIVISION IDIANAPOLIS, INDIANA 46206-6288 X22289A PATRICIA A FOOR /Patricia A Foor/ 02/22/2019 ent Hydra#page1.tif ent Hydra#page2.tif ent Hydra#page3.tif | nt via US Mail. | | | | |
| using a fax number, in Email: Correspondent Name Address Line 1: Address Line 2: Address Line 4: ATTORNEY DOCKET N NAME OF SUBMITTER SIGNATURE: DATE SIGNED: Total Attachments: 5 source=Patent Assignments | f provided; pa : El P. P. IVMBER: : : : : : : : : : : : : : : : : : : | he e-mail address first; if that is un if that is unsuccessful, it will be set atents@lilly.com LI LILLY AND COMPANY O. BOX 6288 ATENT DIVISION IDIANAPOLIS, INDIANA 46206-6288 X22289A X22289A PATRICIA A FOOR /Patricia A Foor/ 02/22/2019 ent Hydra#page1.tif ent Hydra#page2.tif ent Hydra#page3.tif ent Hydra#page4.tif | nt via US Mail. | | | | |

PATENT ASSIGNMENT AGREEMENT

This **PATENT ASSIGNMENT AGREEMENT** (the "*Agreement*") is made and effective as of December 14, 2018, by and between Hydra Biosciences, Inc., a Delaware corporation ("*Seller*"), and Eli Lilly and Company, an Indiana corporation ("*Buyer*").

WHEREAS, Seller is an owner of the patents, patent applications, patent disclosures and related patent rights listed on Schedule 1 (collectively, the "Patents"); and

WHEREAS, Seller desires to sell, and Buyer desires to acquire, all of Seller's right, title and interest in and to the Patents pursuant to that certain Asset Purchase Agreement by and among Seller and Buyer dated as of the date hereof (the "Asset Purchase Agreement").

NOW, THEREFORE, in consideration of entering into the Asset Purchase Agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Seller hereby sells, assigns, set overs and transfers to Buyer, its successors and assigns all of Seller's entire rights, title and interests in and to the Patents, and agrees to sell, assign, set over and transfer to Buyer, its successors and assigns all of Seller's entire right, title and interest in and to the Patents that are completed or come into existence hereafter, including any nonprovisionals, continuations, continuations-in-part, divisionals, reissues, re-examinations, substitutions, and extensions thereof, and any and all patents of the United States and foreign countries that may issue therefrom, and all rights of priority resulting from the filing in the United States of the Patents, and any and all applications for patent and patents issuing therefrom in any and all countries of the world, including all non-provisionals, continuations, continuations-in-part, divisionals, reissues, re-examinations, substitutions, and extensions thereof, and all rights of priority resulting from the filing in the United States of the respective applications for said Patents identified above, the same to be held and enjoyed by Buyer for its own use and enjoyment, and for the use and enjoyment of its successors, assigns and other legal representatives, to the end of the term or terms for which the Patents are or may be granted or reissued as fully and entirely as the same would have been held and enjoyed by the Seller if this Agreement and sale had not been made; together with all claims for damages by reason of past infringements of the Patents including without limitation provisional rights thereto with the right to sue for and collect the same for its own use and benefit, and for the use and on behalf of its successors, assigns and other legal representatives.

Seller agrees that, on request it will sign all lawful papers in connection with all Patents and, with respect thereto, all non-provisionals, continuations, continuations-in-part, divisionals, reissues, re-examinations, substitutions, and extensions thereof, and any and all patents of the United States and foreign countries that may issue therefrom, make all rightful oaths and generally do everything reasonably requested by Buyer to aid Buyer, its successors, assigns and nominees to obtain, maintain, and enforce patent protection in any country for the inventions set forth in the Patents.

In the event of any conflict between this Agreement and the Asset Purchase Agreement, the Asset Purchase Agreement shall control. Nothing in this Agreement shall be deemed to amend or modify in any way any of the terms and conditions of the Asset Purchase Agreement or any rights or obligations of the parties thereto. IN WITNESS WHEREOF, the undersigned has caused this Patent Assignment Agreement to be executed and delivered as of the date first above written.

BUYER:

ELI LILLY AND COMPANY

By: Name: David A. Ricks

Title: President and Chief Executive Officer

SELLER:

HYDRA BIOSCIENCES, INC.

By: Name: Russell Herndon Title: President and Chief Executive Officer

[Signature Page for Patent Assignment Agreement]

IN WITNESS WHEREOF, the undersigned has caused this Patent Assignment Agreement to be executed and delivered as of the date first above written.

BUYER:

ELI LILLY AND COMPANY

By: Name: David A. Ricks Title: President and Chief Executive Officer

SELLER:

HYDRA BIOSCIÉNCES, INC.

By:

Name: Russell Herndon Title: President and Chief Executive Officer

[Signature Page for Patent Assignment Agreement]

PATENT REEL: 048408 FRAME: 0233

SCHEDULE 1

See attached.

Attachment to Schedule 1

| Application Numbe | | Application Statu | | Pub Number | Patent Number | Issue Date | App Take |
|---|--|--|--|--|-----------------------------|----------------------------|--|
| 1008268463 1015202546 | AU | Granted Granted | 23-Jan-2008 23-Jun-2008 | | 2008268463 | | METHODS AND COMPOSITIONS FOR TREATING DISORDERS METHODS AND COMPOSITIONS FOR TREATING DISORDERS |
| 017203705 | AU | Pending | 23-169-2008 | | | | METHODS AND COMPOSITIONS FOR TREATING DISORDERS |
| 8771748.4 2691468 | BE CA | Granted Granted | 23-jun-2008 23-jun-2008 | | 2170309 2691486 | | METHODS AND COMPOSITIONS FOR TREATING DISORDERS METHODS AND COMPOSITIONS FOR TREATING DISORDERS |
| 2962043 | CA. | Published | 23-308-2008 | 2962643 | | | METHODS AND COMPOSITIONS FOR TREATING DISORDERS |
| 8771749.4 | CH CN | Granied | 23-Jun-2008 23-Jun-2008 | | 2170309 ZL200880103802.8 | | METHODS AND COMPOSITIONS FOR TREATING DISORDERS |
| 00880103802.8 | CN | Granted Granted | | CN100751194 | | | METHODS AND COMPOSITIONS FOR TREATING DISORDERS METHODS AND COMPOSITIONS FOR TREATING DISORDERS |
| 01510111699.3 | <u>CN</u> | Published | 23 Jun-2069 | 104825457 | | | METHODS AND COMPOSITIONS FOR TREATING DISORDERS |
| 933711272327.4 8771745.4 | CN DE | Polylished Granted | 23-Jun-2008 23-Jun-2008 | CN1088642542A | 802008047050.4 | 25-Oct-2035 | NETHODS AND COMPOSITIONS FOR TREATING DISORDERS METHODS AND COMPOSITIONS FOR TREATING DISORDERS |
| 8771745.4 | DK. | Granted | 23-366-2008 | 2170305 | 2170309 | 25-Oct-2015 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS |
| 8771749 4 6195618.0 | EP EP | Granded Published | 23-Jon-2008 23-Jon-2008 | | 2170305 | 26-Oct-2016 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS METHODS AND COMPOSITIONS FOR TREATING DISORDERS |
| 6771748.4 | ES | Granted | 23-Joa-2005 | 2370309 | E08771748 | 26-Oct-2018 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS |
| 6771748.4 | E | Granted | 23.Jgn-2008 | | 2370309 | 26-Oct-2018 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS |
| 8771748:4. 8771748:4 | FR GB | Granted Granted | 23-Jun-2008 23-Jun-2008 | | 2170309 2170309 | 26-Oct-2016 26-Oct-2016 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS METHODS AND COMPOSITIONS FOR TREATING DISORDERS |
| 0109110.4 | нĸ | Granted | 23-369-2008 | 1142541A | HK1342541 | 12-Jan-2018 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS |
| 7113931-6 8771749:4 | 1:0% RE | Pending Granted | 23-308-2008 23-308-2008 | 2170309 | 2172309 | 26-Oct-2016 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS METHODS AND COMPOSITIONS FOR TREATING DISORDERS |
| 52/DELNP/2010 | IN. | Cranited | 23-308-2008 | | 294564 | 20-Mar 2618 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS |
| 6771748.4 014-100945 | 11 39 | Granted Granted | 23-Jan-2008 23-Jan-2008 | 2370309 | 502017000003434 5932863 | 26-Oct-2016 13-May-2016 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS METHODS AND COMPOSITIONS FOR TREATING DISORDERS |
| 115-139797 | SP | Granted | 23-340-2008 | | 6258266 | | METHODS AND COMPOSITIONS FOR TREATING DISORDERS |
| 017-131268 8771748.4 | 359 | Published | 23-569-2008 | 2017-165790 | 24 303000 | 26-Oct-2036 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS |
| 3773748.4 | NR. NO | Granted Granted | 23-369-2006 | | 2170309 2170309 | 25-Oct-2015 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS METHODS AND COMPOSITIONS FOR TREATING DISORDERS |
| 5773749.4 | SE | Graniec | 23-108-2008 | 2179309 | 2170309 | 26-Oct-2016 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS |
| 2/144354 58635776 | US | Granled Published | | US-2009-0143377-A1 US-2018-0133170-A1 | 6163761 | 34-Apr-2012 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS METHODS AND COMPOSITIONS FOR TREATING DISORDERS |
| 113202367 | 40 | Granted | 22 Dec 2006 | | 2013202367 | 25-Jan-2017 | TRPA1 INHIBITORS FOR TREATING PAIN |
| 31627386G | AU | Allowed | 22 Dec 2006 | | | | TRPA1 INHIBITORS FOR TREATING PAIN |
| 634152. 6548704.0 | CA | Politished Granted | 22-Dec-2005 22-Dec-2005 | | 1962865 | 21-Aug-2013 | TRPA1 INHIBITORS FOR TREATING PAIN TRPA1 INHIBITORS FOR TREATING PAIN |
| 00680053268.5 | CN | Granted | 22 Dec 2008 | 1013842E1A | ZL200680053268.5 | 07-Dec-2011 | TRPA1 INHIBITORS FOR TREATING FAIN |
| 6848784 0 5948204 0 | DE | Granded | 22-Dec-2006 | | 602006038049.6 1962865 | | TREAT INHIBITORS FOR TREATING PAIN |
| 6848704 0 6848704 0 | ES | Granted Granted | 22-Dec-2006 22-Dec-2006 | 1962855 | 1962855 | 21-Aug-2013 21-Aug-2013 | TRPAT INHIBITORS FOR TREATING PAR. TRPAT INHIBITORS FOR TREATING PAR. |
| 6848754.8 | ĞB | Granted | 22-0ec-2006 | 1962855 | 1952855 | 21-Aug-2013 28-Mar-2014 | TRPAT INHIBITORS FOR TREATING PAIN |
| 9100626.3 412/DELNP/2008 | HK IN | Granted Published | 22-Dec-2006 22-Dec-2006 | 11261 8691 | 1322738 | 20:00:00-2014 | TRPA1 INHIBITORS FOR TREATING PAIN TRPA1 INHIBITORS FOR TREATING PAIN |
| 6848704.0 | ΪĨ | Granted | 22-Dec-2006 | 1962855 | 1962855 | 21-Aug-2013 | TRPA1 INHIBITORS FOR TREATING FAIN |
| 008-547657 015-215448 | 90 30 | Granted Pending | 22-Dec-2006 22-Dec-2006 | | 5658557 | 25-Dec-2015 | TRPA1 INHIBITORS FOR TREATING PAIN TRPA1 INHIBITORS FOR TREATING PAIN |
| 047-153130 | .P | Published | | 2017-260953 | | | TREAT INHIBITORS FOR TREATING PAIN |
| 5148357 | <u>WT</u> | Granted | 22-Dec-2006 | 423619 | 1423639 | 21-Jan-2014 | COMPOUNDS FOR MODULATING TRPA1 FUNCTION |
| 02139287 05109423 | TW TW | Granted Alkwed | 22-Dec-2006 22-Dec-2006 | | 1610684 | 11-Jan-2018 | COMPOUNDS FOR MODULATING TRPAT FUNCTION COMPOUNDS FOR MODULATING TRPAT FUNCTION |
| 07133432 | T\$Y | Pending | 22-Dec-2006 | | | | COMPOUNDS FOR MODULATING TRPAT FUNCTION |
| N645307 2/722467 | US | Granted Granted | 22-Dec-2006 | | 767106182 | | METHODS AND COMPOSITIONS FOR TREATING PAIN METHODS AND COMPOSITIONS FOR TREATING ASTHMA |
| 3/444213 | US . | Granied | | US-2013-0123283-A1 | | | METHODS AND COMPOSITIONS FOR TREATING FAIN |
| 3/966546 | US | Granied | 14-Aug-2013 | US-2014-0221401-A1 | | | METHODS AND COMPOSITIONS FOR TREATING PAIN |
| 5/783530 2/688241 | US | Published Granted | | US-2018-0093986-A1 US-2010-0267750-A1 | 8378542 | 15-May-2812 | METHODS AND COMPOSITIONS FOR TREATING PAIN METHODS AND COMPOSITIONS FOR TREATING PAIN |
| 3/661812 | US | Granted | | US-3013-0303521-A1 | | 24-Apr-2018 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT- |
| \$/922402 | US | Published | 35-Mar-2018 | US-2018-0265511-A1 | | | INDUCED INJURIES. COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT- |
| | | | | | | | INDUCED INJURIES |
| 3/120891 | US | Published Granted | | US-2012-0046305-A1 US-2010-0249154-A1 | 8353636 | 29-Jan-2013 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO TRPAT |
| 3/735624 | US | Granted | 68-Jan-2013 | US-2614-0005208-A1 | 9006207 | 14-Apr-2015 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO TRIPAT |
| 4/641736 | US | Granted | | US 2018-0035499 A1 | | 16-May-2017 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO TRPA1 |
| 2/696618 3/861858 | US | Granted Granted | 29-Jan-2010 12-Apt-2013 | | 8530487 8952023 | 10-500-2013 16-Feb-2015 | COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO TRPAT COMPOUNDS USEFUL FOR TREATING RUURIES FROM WARFARE AGENTS |
| 3/963586 | US | Granted | 69-Aug-2013 | | 9012465 | 21-Apr-2015 | COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO TRPA1 |
| 4/616100 3/593572 | 05 | Granted Published | | US-2016-0009708-A1 US-2013-0465427-A1 | 9505756 | 29-Nov-2016 | COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO TRPAT COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT- |
| | 1.0 | C COMBREM | and the set of the set | | | | INDUCED INJURIES |
| 2/465187 | US | Granted | 14-May-2009 | US-2012-0108613-A1 | 8318728 | 27-Nov-2012 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT- |
| 3/655336 | US | Granted | 18-06-2012 | US-2013-0165454-A1 | 8710052 | 23-Apr-2014 | INDUCED INJURIES COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT- |
| | | | | | | | INDUCED INJURIES |
| 12158050 | UŞ | Granted | 05-Mar-2014 | US-2014-0303192-A1 | 9260431 | 16-Feb-2016 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT- INDUCED INJURIES |
| 4/989030 | us | Granied | 86-Jon-2016 | US 2015-0354379 A1 | 9960968 | 29-May-2018 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT- |
| | 1 | | | 1 | | | INDUCED INJURIES |
| 100 ACT 12 | 1000 | That is the | 33.2 | have address to the state | | | |
| 5/984653 | us | Published | 27-Apr-2018 | US-2018-0311248-A1 | | | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT- |
| 54984653 37782488 | US US | Published Granted | 27-Apr-2018 08-Jun-2011 | US-2018-0311248-A1 US-2013-0310346-A1 | 9250430 | 16-Feb-2016 | COMPOUNDS AND COMPOSITIONS FOR TREATING CREMICAL WARFARE ACENT- INDUCED INJURIES USE OF TREAT ANTAGONISTS TO PREVENT OF TREAT INFECTIONS CAUSED BY |
| 3/782488 | US | Granted | 68-Jun-2013 | US-2013-0340345-A1 | 3350430 | 16-Feb-2016 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT- INCIDED INJURIES USE OF TRPAT ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BICLOGICAL-WARFARE AGENTS |
| 9782488 1/990455 | US US | Granted Published | 08-Jun-2014 07-Jan-2016 | US-3013-0310345-A1 2017-0151248 | 3350430 | 16-Feb-2016 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT- INDUCED INJURIES USE OF TREAT ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BIOLOGICAL-WARFARE AGENTS USE OF TRPAT ANTAGONISTS TO PREVENT ON TREAT INFECTIONS CAUSED BY BIOLOGICAL-WARFARE AGENTS |
| V762485 V990455 V150101221 | US US AR | Granted Published Published | 08-Jun-2011 07-Jan-2016 23-Aps-2015 | US-3013-0310345-A1 2017-0151248 | 3350430 | 16-Fab-2016 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT- INCUCED INJURIES USE OF TREAT INTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BIOLOGICAL-WARFARE AGENTS USE OF TREAT ANTAGONISTS TO PREVENT ON TREAT INFECTIONS CAUSED BY BIOLOGICAL-WARFARE AGENTS INVESTING THE TRANSFERT RECEPTOR POTENTIAL AN ION CHANNEL. |
| v782488 v990455 v150101221 v15252007 | US US AR AU SA | Granted Published | 08-Jun-2014 07-Jan-2016 | US 2013-0310345-A1 2017-0351248 0103165 | 3350430 | 16.Fsb-2016 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT- INDUCED INJURIES USE OF TREAT ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BIOLOGICAL-WARFARE AGENTS USE OF TRPAT ANTAGONISTS TO PREVENT ON TREAT INFECTIONS CAUSED BY BIOLOGICAL-WARFARE AGENTS |
| V782488 V990455 V950101221 V9252007 V45789 V9560022160 5 | US US AR AU CA | Granted Published Published Pedding Published Published | 08-Jun-2011 07-Jan-2016 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 | US-2013-0310345-A1 2017-0151248 0100165 2945789 CN106573834A | 3350430 | 16.Fsb-2016 | COMPOUNDS AND COMPOSITIONS FOR THEATING CHEMICAL WARFARE AGENT- INDUCED INJURIES USE OF TRAT ANTAGONISTS TO PREVENT OF TREAT INFECTIONS CAUSED BY BICLOGICAL-WARFARE AGENTS USE OF TRATA INTAGONISTS TO PREVENT ON TREAT INFECTIONS CAUSED BY SICLOGICAL-WARFARE AGENTS INHIBITION THE TRANSIENT PECEPTOR POTENTIAL ATION CHANNEL INHIBITION THE TRANSIENT RECEPTOR POTENTIAL ATION CHANNEL |
| V782488 V990455 V150101221 V15252007 45789 V1550222160 5 V722319.5 | US US AE CA CA EP | Granted Published Published Published Published Published Published | 08-Jun-2011 07-Jan-2016 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 | US 3013 0310345-A1 2017-0151248 0103165 2945789 CN106573334A 3134410 | 9353430 | 16.Fsb-2016 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT- INFLUED INJURIES USE OF TRAFATANTAGONISTS TO PREVENT ON TREAT INFECTIONS CAUSED BY BIOLOGICAL-WARFARE AGENTS USE OF TRAFAT INTRAGENISTS TO PREVENT ON TREAT INFECTIONS CAUSED BY BIOLOGICAL-WARFARE AGENTS INVERTING THE TRANSIENT RECEPTOR POTENTIAL AS ION CHANNEL. INFERTING THE TRANSIENT RECEPTOR POTENTIAL AS ION CHANNEL. |
| 7762488 7590455 150101221 15252007 15600221805 722319.5 104857.6 104857.6 | US US AE CA CA EP EX | Granted Published Published Padring Published Published Published Published Published | 08-Jun-2011 07-Jan-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2018 23-Apr-2018 | US 3013 0310345-A1 2017-0151248 0100165 2945789 CN106573334A 3134410 1227335 | 9356430 | 16.Fsb-2016 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT- INDUCED INJURIES USE OF TREAT ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BICLOGKAL-WARFARE AGENTS USE OF TREAT INTRGOMISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY SICLOGKAL-WARFARE AGENTS USE OF TREAT INTRGOMISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY SICLOGKAL-WARFARE AGENTS INFIBITING THE TRANSIENT RECEPTOR POTENTIAL AS ION CHANNEL. INFIBITING THE TRANSIENT RECEPTOR POTENTIAL AS ION CHANNEL. |
| 5762488 8590455 1150101221 115252007 145799 1155022180 5 5722319.5 1108657.8 1108657.8 1110279.2 110279.2 | US AR AS CA CA EP HK HK | Granted Fublished Padisabed Padisabed Published Published Published Published Published Published Published Published | 68-Jun-2011 67-Jan-2016 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 | US 3013 0310345-A1 2017-0151248 0100165 2945789 CN106573334A 3134410 1227335 | 3350430 | 16.Fab-2018 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT- INFLUED INJURIES USE OF TREAT ANTAGONISTS TO PREVENT ON TREAT INFECTIONS CAUSED BY BIOLOGICAL-WARFARE AGENTS USE OF TREAT ANTAGONISTS TO PREVENT ON TREAT INFECTIONS CAUSED BY BIOLOGICAL-WARFARE AGENTS INFUSITING THE TRANSIENT RECEPTOR POTENTIAL AS ION CHANNEL. INFUSITING THE TRANSIENT RECEPTOR POTENTIAL AS ION CHANNEL. |
| 9762488 8990455 9150101221 915252007 91550122160 5 9722333.5 712533.5 7110855.7.6 7110857.6 7110857.7.6 71108279.2 91617012296 916152793 | US US AE CA CA EP EX | Granted Published Published Padring Published Published Published Published Published | 68-Jun-2011 07-Jan 2016 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 | US 2013-0340346 A1 2017-0151248 0100365 2945789 CN:06673834A 3534410 1237333 1235524A | 9350430 | 16.Fab-2018 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT- INDUCED INJURIES USE OF TREAT ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BICLOCKAL-WARFARE AGENTS USE OF TREAT INTIGODISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BICLOCKAL-WARFARE AGENTS INHIBITING THE TRANSIENT RECEPTOR FOTENTIAL AT ION CHANNEL INHIBITING THE TRANSIENT RECEPTOR POTENTIAL AT ION CHANNEL |
| 9762488 NS90455 NS9 | US US AR AU CA CA CA EP HK HK HK N JP TDY US | Granted Fublished Published Published Published Published Published Problemed Pending Pending Pending Pending | 68-Jun-2034 07-Jan 2036 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 23-Apr-2015 22-Apr-2015 22-Apr-2015 22-Apr-2015 23-Apr-2015 23-Apr-2015 | US 2013-0340346 A1 2017-0151248 0100365 2945789 CN:06673834A 3534410 1237333 1235524A | | 16.Fab 2016 | COMPOUNDS AND COMPOSITIONS FOR THEATING CHEMICAL WARFARE AGENT- NEWCED INJURIES USE OF TREAT ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BICCOGKAL-WARFARE AGENTS USE OF TREAT ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY SICLOGKAL-WARFARE AGENTS INHIBITION THE TRANSIENT RECEPTOR POTENTIAL AT ION CHANNEL INHIBITION THE TRANSIENT RECEPTOR POTENTIAL AT ION CHANNEL |
| V762498 V950455 V950455 V159101221 V15252007 V45799 V15252183 5 7225319.5 V108267.6 V108267.6 V108276.2 V108279.2 V109279.2 V1 | US US AR AU CM CM CM EP HK HK N SP TW US VE | Granted Published Published Ponting Published Published Published Published Published Pending Published Published Published Published | 68 Jun 2011 07 Jun 2016 23 Apr-2016 23 Apr-2015 23 Apr-2015 23 Apr-2015 23 Apr-2015 23 Apr-2018 23 Apr-2018 23 Apr-2018 23 Apr-2018 23 Apr-2018 23 Apr-2018 23 Apr-2018 23 Apr-2015 29 Apr-2015 | US 2613 0340346 A1 2617-0151248 8102165 2945785 CN 106573034A 3134410 1237335 1236524A; 201625618 | | 16.Fab 2016 | COMPOUNDS AND COMPOSITIONS FOR THEATING CHEMICAL WARFARE AGENT INDUCED INJURIES USE OF TREAT ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BICLOGKAL-WARFARE AGENTS USE OF TREAT INTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY SICLOGKAL-WARFARE AGENTS USE OF TREAT INTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY SICLOGKAL-WARFARE AGENTS INFIBITING THE TRANSIENT RECEPTOR POTENTIAL AS ION CHANNEL INFIBITING THE TRANSIENT RECEPTOR POTENTIAL AS ION CHANNEL |
| 9762488 N990455 1759101221 175252007 147789 1750223185 1702657.6 1710279.2 17107 | US US AB AC CA CA CA CA CA CA CA CA CA CA CA CA | Granted Published Pending Published Published Published Published Published Pending Panding Published Panding Published Published Published Published Published | 68 Jun 2011 67 Jan 2016 23 Apr.2015 23 Apr.2015 29 Mar.2016 29 Mar.2016 29 Mar.2016 18 Sapr.2015 | US 2013-0340346-A1 2017-0151248 0102165 2945785 CN106573834A 3734410 1237333 1236524A 201625618 US 2018-0230149 A1 | | 16.Fab.2016 | COMPOUNDS AND COMPOSITIONS FOR THEATING CHEMICAL WARFARE AGENT: NEUGEO INURRES USE OF TREAT ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BICK OGKAL-WARFARE AGENTS USE OF TREAT ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY SIGLOGICAL-WARFARE AGENTS INVESTIGATION OF THE TRANSIENT RECEPTOR POTENTIAL AT ON CHANNEL. INVESTIGATION THE TRANSFERT RECEPTOR POTENTIAL AT ON CHANNEL. INVESTIGATION THE TRANSFERT RECEPTOR POTENTIAL AT ON CHANNEL. INVESTIGATION THE TRANSFERT RECEPTOR POTENTIAL AT ON CHANNEL. INVESTIGAT |
| 9762488 8590455 9769101221 115252007 447059 115252007 1447059 115252007 115252185 115522185 11552524 11652799 1165279 116527 | US US US CSA CSA CSA CSA CSA CSA CSA CS | Granted Granted Published Pending Published Published Published Published Published Pending Pending Published Published Published Published Published Published | 68 Jun 2011 67 Jan 2016 23 Apr.2015 23 Apr.2015 18 Sep.2015 18 Sep.2015 18 Sep.2015 18 Sep.2015 | US 2013 0340346 A1 2017-0151248 8100165 2945785 0100165 2945783 2945785 015025618 1237335 1236524A: 201525618 US 2018-0230149 A1 2961412 2961412 | | 16.Fab-2616 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT NEWCED INJURIES USE OF TRAFAT ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BICLOGICAL-WARFARE AGENTS USE OF TRAFAT INTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY SICLOGICAL-WARFARE AGENTS USE OF TRAFAT INTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY SICLOGICAL-WARFARE AGENTS INVESTING THE TRANSIENT RECEPTOR POTENTIAL AS ION CHANNEL INVESTING THE TRANSIENT RECEPTOR POTENTIAL AS ION CHANNEL |
| 9762488 1159061221 11522007 11522007 11522007 11550221655 11550221655 11550221655 11550221655 116552799 11617022866 116552799 11617022866 116552799 116532732 115592504844 115597332 115592504844 115597532 | US US AR CA CA CA CA EP HK HK HK HK HK HK CA CA CA CA CA CA CA CA CA CA CA CA CA | Granted Frabished Poblished Poblished Poblished Poblished Problemed Problemed Poblished Poblished Poblished Poblished Poblished Poblished Poblished Poblished Poblished Poblished Poblished Poblished Poblished Poblished | 68 Jun 2011 67 Jan 2015 23 Apr.2015 23 Apr.2015 24 Apr.2015 28 Mar.2015 28 Mar.2015 18 Sep.2015 18 Sep.2015 18 Sep.2015 18 Sep.2015 | US 2013-0340346 A1 2017-0151248 0102165 2945785 0N106573834A 3134410 1237335 1236524A 201625618 20162512 201625618 201625618 20162512 201625 20165 2016 2016 2016 2016 2016 2016 2016 2016 | | 16.Fsb-2016 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT- NEUGED INURIES UGE OF TRAIT ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BICK OGKAL-WARFARE AGENTS USE OF TREAT INITIAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BICK OGKAL-WARFARE AGENTS INHIBITION THE TRANSIENT PECEPTOR POTENTIAL AT ION CHANNEL INHIBITION THE TRANSIENT RECEPTOR P |
| 9762488 8590455 9769101221 115252007 447059 115252007 1447059 115252007 115252185 115522185 11552524 11652799 1165279 116527 | US US US CSA CSA CSA CSA CSA CSA CSA CS | Granted Granted Published Pending Published Published Published Published Published Pending Pending Published Published Published Published Published Published | 68 Jun 2011 67 Jan 2015 23 Apr.2015 23 Apr.2015 29 Mar.2015 29 Mar.2015 18 Sep.2015 18 Sep.2015 18 Sep.2015 18 Sep.2015 18 Sep.2015 18 Sep.2015 18 Sep.2015 18 Sep.2015 18 Sep.2015 18 Sep.2015 19 Sep.2015 19 Sep.2015 19 Sep.2015 19 Sep.2015 19 Sep.2015 19 Sep.2015 19 Sep.2015 20 Se | US 2013-0340346-A1 2017-0151248 0102165 2945785 CN106573834A 1237335 1236524A 201625618 US 2018-0230149-A1 2961412 2961412 2961412 2961412 2961412 2961412 2961412 | | 16.Fsb-2016 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT- NEWLED INJURIES USE OF TRAFAT ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BICLOGICAL-WARFARE AGENTS USE OF TRAFAT INTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY SICLOGICAL-WARFARE AGENTS UNE OF TRAFAT INTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY SICLOGICAL-WARFARE AGENTS INVESTING THE TRANSIENT RECEPTOR POTENTIAL AS ION CHANNEL. INVESTING THE TRANSPORT RECEPTOR PO |
| 9762488 1950101221 1950101221 1950101221 1950502007 485769 19565022180 5 19565022180 5 19565022180 5 195752878 195950404 195950404 4 195950404 4 195950404 4 19774605 2 1974505 2 1975 | US US AS AS CA CA EP HK HK HK HK HK EP HK EP HK CA CA CA CA CA CA CA SP TW US CA SP TW SP TW SP TW SP CA CA CA SP CA ST ST CA ST ST CA ST CA ST CA ST CA ST CA ST CA ST ST ST ST ST ST ST ST ST ST ST ST ST | Granted Granted Published Publ | 68 Jun 2011 67 Jun 2011 23 Apr.2015 23 Apr.2015 18 Sep.2015 18 Sep.2015 19 Sep.2015 19 Sep.2015 19 Sep.2015 19 Sep.2015 19 Sep.2015 | US 2013 0340346 A1 2017 0151248 0102165 2945705 CN106573834A 1225034A 201625618 US 2018-0230149 A1 201625618 US 2018-0230149 A1 201625618 201625618 201625618 201625618 2017-528490 | | 16.Fsb-2016 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT- NEUCED INJURIES USE OF TREAT ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BICS COCKAL-WARFARE AGENTS USE OF TREAT ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY SICLOCICAL-WARFARE AGENTS INJURY OF TREATING THE TRANSIENT RECEPTOR POTENTIAL AS ION CHANNEL INJURY THE TRANSIENT RECEPTOR POTENTIAL AS ION CHANNEL |
| 9762488 8790455 9769101221 115252007 145252007 145252007 145252007 145252007 1452523 13580221805 1410259 1410259 1410259 1410259 14112581 145317332 14542253 185762,045 115500520464,4 147763723 197745052 117763723 1177763723 1177763723 11777775 1177777777777777777777777777 | US US US AR AS CS CS HK HK HK HK HK HK N US CS CS HK HK K N SP TW SP TW | Granted Granted Published Pending Published Published Published Published Published Pending Pending Pending Published Published Published Published Published Published Published Published Published Published Published Published Published Published | 68 Jun 2011 67 Jan 2016 23 Apr 2016 24 Apr 2016 24 Apr 2016 18 Seq 2016 18 Seq 2016 19 Sep 2016 19 Se | US 2613-0340346-A1 2617-0351248 8102165 2945785 CN106573334A 3134410 1237335 1236524A 314525638 US 2018-0230149-A1 2961312 CN106715332A 3193880 2017-528490 2017-528490 2017-528490 | | 16.Fsb-2016 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT- NEUGEO INURRIES USE OF TREAT ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BICK OCKAL-WARFARE AGENTS USE OF TREAT ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BICK OCKAL-WARFARE AGENTS INVESTIGATION OF THE TREAT OF THE AT INFECTIONS CAUSED BY BICK OCKAL-WARFARE AGENTS INVESTIGATION OF THE TREAT OF THE AT INFECTIONS CAUSED BY BICK OCKAL-WARFARE AGENTS INVESTIGATION OF THE TREAT OF THE AT INFECTIONS CAUSED BY BICK OCKAL-WARFARE AGENTS INVESTIGATION OF THE TREAT OF THE AT INFORMATION INVESTIGATION OF THE TRANSIENT RECEPTOR POTENTIAL AS ION CHANNEL INVESTING THE TRANSENT RECEPTOR POTENTIAL AS ION CHANNEL INVESTING THE TRANSIENT R |
| 9762488 1950101221 1950101221 1950101221 1950502007 485769 19565022180 5 19565022180 5 19565022180 5 195752878 195950404 195950404 4 195950404 4 195950404 4 19774605 2 1974505 2 1975 | US US AS AS CA CA EP HK HK HK HK HK EP HK EP HK CA CA CA CA CA CA CA SP T D SP T D SP T D SP T D S CA S CA S CA S CA S CA S CA S CA S | Granted Granted Published Publ | 68 Jun 2011 67 Jan 2016 23 Apr 2016 24 Apr 2016 24 Apr 2016 18 Seq 2016 18 Seq 2016 19 Sep 2016 19 Se | US 2013 0340346 A1 2017-0151248 0102165 2945785 2945785 0102165 2945785 2945785 294573334 12352334 1235234 2016256 18 US 2016-0250143 A1 2961312 CN106715430A 3193886 2017-528480 2017-528480 2015256 19 US 2017-5275295 A1 | | 16.Fsb-2616 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT- NEUCED INJURIES USE OF TREAT ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BICS COCKAL-WARFARE AGENTS USE OF TREAT ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY SICLOCICAL-WARFARE AGENTS INJURY OF TREATING THE TRANSIENT RECEPTOR POTENTIAL AS ION CHANNEL INJURY THE TRANSIENT RECEPTOR POTENTIAL AS ION CHANNEL |